Recent Research Analysts’ Ratings Changes for Natera (NTRA)

A number of research firms have changed their ratings and price targets for Natera (NASDAQ: NTRA):

• 6/23/2026 – Natera had its price target raised by BTIG Research from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 6/11/2026 – Natera is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $275.00 price target on the stock.
• 6/5/2026 – Natera is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $245.00 price target on the stock.
• 6/5/2026 – Natera is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $245.00 price target on the stock.
• 6/2/2026 – Natera is now covered by Wolfe Research. They set an “outperform” rating and a $260.00 price target on the stock.
• 6/1/2026 – Natera was upgraded by Wolfe Research to “strong-buy”.
• 5/12/2026 – Natera had its “overweight” rating reaffirmed by Piper Sandler. They now have a $249.00 price target on the stock.
• 5/11/2026 – Natera had its price target lowered by BTIG Research from $260.00 to $250.00. They now have a “buy” rating on the stock.
• 5/9/2026 – Natera was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/8/2026 – Natera was given a new $265.00 price target by Robert W. Baird.
• 5/8/2026 – Natera had its “outperform” rating reaffirmed by Evercore Inc. They now have a $270.00 price target on the stock.
• 5/8/2026 – Natera had its price target raised by JPMorgan Chase & Co. from $260.00 to $265.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Natera had its price target raised by Wells Fargo & Company from $215.00 to $220.00. They now have an “equal weight” rating on the stock.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 3,070 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total transaction of $594,781.80. Following the completion of the sale, the chief financial officer directly owned 58,291 shares of the company’s stock, valued at approximately $11,293,298.34. This trade represents a 5.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the sale, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 162,342 shares of company stock worth $35,283,396. Corporate insiders own 5.05% of the company’s stock.

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.